TASK-1 blockers are promising drugs for the treatment of AFib3–5,18 and OSA/CSA3,7 and several TASK-1 blockers are undergoing clinical trials for the treatment of OSA (BAY2586116) and AFib (A293 = AVE1231, doxapram). The gene discussed is KCNK3; the disease is obstructive sleep apnea syndrome.